A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy

NCT ID: NCT01517880

Last Updated: 2016-06-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 46 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-05-31
• Study Completion Date: 2013-11-30

Brief Summary

GNE myopathy or hereditary inclusion body myopathy (HIBM) is a severe progressive metabolic myopathy caused by a defect in the biosynthetic pathway for sialic acid (SA).

Detailed Description

GNE myopathy or hereditary inclusion body myopathy (HIBM) is a severe progressive metabolic myopathy caused by a defect in the biosynthetic pathway for sialic acid (SA). Substrate replacement therapy is a potential therapeutic strategy based on the success of replacing missing SA and reducing muscle disease in a relevant mouse model of the human disease (Malicdan et al., 2009). Successful use of SA replacement therapy in humans is believed to depend upon providing steady long-term exposure to the compound in an extended release form (such as Sialic Acid-Extended Release [SA-ER]), given SA's short half-life. Following a Phase 1 study to establish the pharmacokinetics (PK) for SA-ER, Ultragenyx is conducting this study to assess the dose and potential pharmacodynamic effect of restoring sialylation of muscle by treatment with SA-ER at two dose levels as compared to placebo when administered over two 24 week periods of time. The study will also evaluate safety, as well as the effect of SA-ER on clinical measures of muscle strength, mobility, function and self-reported disability and quality of life. Effects on muscle volume/mass and function and on serum biomarkers will be evaluated as exploratory measures. These data should allow the selection of a dose and the appropriate design for a Phase 3 clinical study.

Conditions

GNE Myopathy; Hereditary Inclusion Body Myopathy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

6,000 mg SA-ER

Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).

Group Type: EXPERIMENTAL

Sialic Acid Extended Release (SA-ER)

Intervention Type: DRUG

SA-ER will be administered in doses of 3000mg per day or 6000mg per day

Placebo

Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (48 weeks total study duration).

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).

3,000 mg SA-ER

Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).

Group Type: EXPERIMENTAL

Sialic Acid Extended Release (SA-ER)

Intervention Type: DRUG

SA-ER will be administered in doses of 3000mg per day or 6000mg per day

Interventions

Sialic Acid Extended Release (SA-ER)

SA-ER will be administered in doses of 3000mg per day or 6000mg per day

Intervention Type: DRUG

Placebo

Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Must be between 18 and 65 years of age, inclusive.

2. Must be willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.

3. Must have a documented diagnosis of GNE myopathy, HIBM, distal myopathy with rimmed vacuoles (DMRV), or Nonaka disease due to previously demonstrated mutations in the gene encoding the GNE/MNK enzyme. Genotyping will not be conducted in this protocol.

4. Must be able to walk 20 meters independently (may use orthotics and assistive devices).

5. Must be able to provide reproducible force in bilateral elbow flexors and knee extensors during hand-held dynamometry testing (unilateral between test variability of < 15% for both muscle groups).

6. Must be willing and able to comply with all study procedures including fine needle muscle biopsies of the upper (e.g., triceps brachii or posterior deltoid) and lower (e.g., biceps femoris or vastus lateralis) extremities at Baseline and 24 and 48 weeks.

7. Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.

8. Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause for at least two years, or have had tubal ligation at least one year prior to Screening, or who have had total hysterectomy.

Exclusion Criteria

1. Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.

2. Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.

3. Ingestion of N-acetyl-D-mannosamine (ManNAc), SA, or related metabolites; intravenous immune globulin (IVIG); or anything that can be metabolized to produce SA in the body for the prior 60 days.

4. Has a condition of such severity and acuity, in the opinion of the investigator, that it warrants immediate surgical intervention or other treatment or may not allow safe participation in the study.

5. Has had any hypersensitivity to SA or its excipients that, in the judgment of the investigator, places the subject at increased risk for adverse effects.

6. Has a concurrent disease or condition that, in the view of the principal investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or would affect safety.

7. Has serum transaminase (i.e., alanine aminotransferase [ALT], aspartate aminotransferase [AST], or gamma-glutamyl transpeptidase [GGT]) levels greater than three times the upper limit of normal or serum creatinine of greater than 2.0 mg/dL.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ultragenyx Pharmaceutical Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alan Pestronk, MD

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Perry Shieh, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Yoseph Caraco, MD

Role: PRINCIPAL_INVESTIGATOR

Hadassah University Hospital

Heather Lau, MD

Role: PRINCIPAL_INVESTIGATOR

NYU Langone Health

Locations

UCLA Medical Center

Los Angeles, California, United States

Washington University School of Medicine

St Louis, Missouri, United States

New York University School of Medicine

New York, New York, United States

Hadassah University Hospital

Jerusalem, , Israel

Countries

United States; Israel

Other Identifiers

UX001-CL201

Identifier Type: -

Identifier Source: org_study_id